Flexion Phase II data for FX005 gives clinical PoC in arthritis pain
This article was originally published in Scrip
Flexion Therapeutics reported topline data from a Phase II proof-of-concept study that showed that its lead anti-inflammatory drug candidate FX005 was well-tolerated, provided sustained pain relief and improved joint function for patients with moderate osteoarthritis in the knee.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.